Connexin 43 expression is associated with poor survival in patients with esophageal squamous cell carcinoma

Introduction

Esophageal squamous cell carcinoma (ESCC) is the sixth most common type of cancer in Japan, and ESCC-related mortality has been steadily increasing in recent years. ESCC is often diagnosed at an advanced stage, and the 5-year survival rate of patients who undergo curative surgery is only 20–30%. In our hospital, we have encountered a number of patients who developed tumor recurrence or distant metastasis during the early stages of the disease, within a short period of time after surgery. Recent molecular biological studies have revealed that esophageal cancer is caused by the accumulation of multiple genetic defects in dominant oncogenes and tumor suppressor genes. In order to elucidate the role of connexin 43 (Cx43) in ESCC, the expression status of Cx43 in patients with ESCC was evaluated (1–7). In addition, the associations between Cx43 expression and clinicopathological characteristics or prognosis were analyzed.

Patients and methods

Patients and tissue samples

Samples were obtained from 98 patients with primary ESCCs. The patients had undergone radical esophagectomy, without any preoperative induction therapy, at the Department of Surgery II, Nagoya City University Medical School (Nagoya, Japan) between 1997 and 2006. The study design was approved by the institutional review board of our university, and written consent was obtained from all the patients. The tumors were classified according to the guidelines for clinical and pathological studies on carcinoma of the esophagus established by the Japanese Society for Esophageal Diseases (8). Tissue specimens were collected from 79 men and 19 women with a mean age of 63.5±8.3 years (range, 46–78 years). Tissues collected for immunohistochemistry were fixed in formalin and embedded in paraffin.

Immunohistochemistry

Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded ESCC tissues. The paraffin-embedded tumor sections were deparaffinized, rehydrated, heat-treated by microwaving in 10 mM citrate buffer for 15 min for antigen retrieval, and cooled to room temperature. The sections were then treated with 0.3% H2O2 in methanol for 30 min to neutralize endogenous peroxidase activity, blocked with Block ace (DS Pharma Biomedical, Osaka, Japan) for 10 min, and incubated with primary monoclonal anti-Cx43 antibody (cat. no. sc-59949; 1:500 dilution; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4°C. Immunoreactive protein was detected with a Dako Envision+ System, horseradish peroxidase (substrate, diaminobenzidine) and the sections were counterstained with hematoxylin. Cx43 immunostaining was subjectively assessed by two independent investigators (T.T. and H.I.) using light microscopy. The intensity of Cx43 immunostaining was classified into 4 grades (0–3), where grades 0 and 1 were defined as low expression, and grades 2 and 3 were defined as high expression.

Statistical analysis

Statistical analysis was performed using the EZR software package (Saitama Medical Center, Jichi Medical University, Saitama, Japan). The Chi-square test was used to analyze the association between immunohistochemical analysis and the clinical and histopathological parameters of the patients. The survival of ESCC patients following surgery was assessed using the Kaplan-Meier method, and survival times were compared using the log-rank test. The data are expressed as mean ± standard deviation. Multivariate analysis was performed using the Cox regression and logistic multivariate regression models. In all the analyses, P-values of <0.05 indicated statistically significant differences.

Results

Cx43 immunostaining

Of the 98 patients enrolled in this study, 62 (63.3%) were high and 36 (37.7%) were low for Cx43 expression. Cx43 expression was observed in epithelial, muscle and tumor cells. Representative cases of immunostaining are shown in Fig. 1.

Figure 1. Immunohistological analysis of esophageal cancer using anti-connexin 43 antibody staining. Magnification. ×200.

Association between clinicopathological characteristics and Cx43 expression

The correlations between immunostaining for Cx43 and the clinicopathological characteristics of the patients are presented in Table I. No significant correlations were observed between Cx43 expression and clinicopathological characteristics such as age, gender, T status, N status, stage, lymphatic invasion, venous invasion and differentiation (Table I). We subsequently investigated the correlation between immunostaining for Cx43 and survival in patients with ESCC after surgery (median follow-up, 28 months). The patients in the Cx43-high group exhibited significantly shorter survival following surgery compared with patients in the Cx43-low group (P=0.0188, log-rank test; Fig. 2).

Figure 2. Survival rate of patients with esophageal squamous cell carcinoma. Cx43, connexin 43. H, high; L, low.

Table I. Association between clinicopathological characteristics and connexin 43 expression.

Table I.

Association between clinicopathological characteristics and connexin 43 expression.

Characteristics	Cases (n=98)	High expression (n=62)	Low expression (n=36)	P-value
Age, years				1
>65	44	28	16
<65	54	34	20
Gender				0.792
Male	79	49	30
Female	19	13	6
Primary tumor
Tis	1	0	1	0.00284
1	31	12	19
2	15	13	2
3	25	19	6
4	26	18	8
Tis-T2	47	25	22	0.06
T3,4	51	37	14
Lymph node metastasis				0.397
Negative	42	24	18
Positive	55	37	18
Histological differentiation				0.481
High	32	23	9
Moderate	52	31	21
Poor	14	8	6
Lymphatic invasion				0.343
Positive	72	48	24
Negative	26	14	12
Venous invasion				0.281
Positive	64	43	21
Negative	34	19	15

Uni- and multivariate analysis for clinicopathological variables of Cx43 expression

The univariate analysis revealed that, among the clinicopathological factors, tumor status [risk ratio (RR)=6.399; P<0.01], lymph node status (RR=4.358; P<0.01), lymphatic invasion (RR=6.952; P=0.001236), venous invasion (RR=6.099; P=0.000157) and Cx43 expression (RR=2.282; P=0.02324) were all statistically significant prognostic factors (Table II). The multivariate analysis revealed that tumor status (RR=4.15; P<0.01) and lymph node status (RR=3.213; P=0.002) were independently associated with an unfavorable prognosis in patients with ESCC (Table III). The RR for Cx43 was 2.017.

Table II. Univariate analysis for clinicopathological variables of connexin 43 expression.

Table II.

Univariate analysis for clinicopathological variables of connexin 43 expression.

Variables	Risk ratio	95% confidence interval	P-value
Primary tumor			<0.01
Tis-T2	1
T3, 4	6.399	3.025–13.54
Lymph node metastasis			<0.01
Negative	1
Positive	4.358	2.078–9.14
Lymphatic invasion			0.001236
Negative	1
Positive	6.952	2.114–22.55
Venous invasion			0.000157
Negative	1
Positive	6.099	2.388–15.58
Connexin 43 expression			0.02324
Low	1
High	2.282	1.119–4.653

Table III. Multivariate analysis for clinicopathological variables of connexin 43 expression.

Table III.

Multivariate analysis for clinicopathological variables of connexin 43 expression.

Variables	Risk ratio	95% confidence interval	P-value
Primary tumor			<0.01
Tis-T2	1
T3, 4	4.15	1.9220–8.959
Lymph node metastasis			0.002
Negative	1
Positive	3.213	1.498–6.888
Lymphatic invasion			0.8384
Negative	1
Positive	1.208	0.1967–7.418
Venous invasion			0.2075
Negative	1
Positive	2.534	0.5968–10.760
Connexin 43 expression			0.058
Low	1
High	2.017	0.8936–4.1701

Discussion

Gap junctions, which were first described in the early 1960s, are cell membrane junctions responsible for intercellular communication, and are involved in tissue homeostasis, proliferation and differentiation. Disruption of this mechanism may facilitate the development of several disorders.

Cx proteins are involved in the function of gap junctions. Indeed, the primary function of Cx is to form conduits between neighboring cells; these conduits mediate the intercellular exchange of small cytoplasmic molecules. Cxs constitute a family of structurally related transmembrane proteins that connect two adjacent cells by forming gap junctions. Each gap junction is composed of two hemichannels or connexons, and each connexon is composed of six Cx proteins. Cxs coordinate cell-to-cell communication by allowing the direct transfer of molecules <1,000 Daltons between cells. Over 20 types of Cxs have been identified to date. Cx43, which was the focus of this study, is expressed in the central nervous system, heart, bone and a number of other organs.

Several studies have demonstrated that Cx proteins often function as tumor suppressors (1–3). Additionally, Li et al previously reported the role of Cx43 in metastatic breast cancer cells (9). Their results demonstrated that the expression of Cx43 in breast cancer cells decreases the metastatic potential of the cells through a mechanism involving N-cadherin expression and apoptosis, which is independent of gap junctional communication. In non-small-cell lung cancer, reduced expression of Cx43 and E-cadherin has been found to be significantly correlated with poor differentiation, advanced TNM stage and lymph node metastasis, suggesting that concurrent reduction of Cx43 and E-cadherin expression may contribute to the development of lung cancer (10). Thus, Cx43 may induce E-cadherin expression, thereby inhibiting cell proliferation and lung cancer progression. In a study on Cx43 in colon cancer, Ismail et al analyzed the expression of Cx43 in samples from 80 cases of histopathologically confirmed and clinically diagnosed human colon cancer and in adjacent control tissues, and assessed the correlations with the clinicopathological variables (11). The expression of Cx43 was found to be significantly downregulated (75%) in cancer samples compared with that in adjacent control tissues. Moreover, Cx43 downregulation was significantly associated with histological type and tumor invasion properties of the cancer. Additionally, Bigelow et al performed gap junction activity assays and protein analysis to evaluate the effects of Cx43 overexpression in SW480 human colorectal cancer cells (2) and demonstrated that overexpression of Cx43 in SW480 cells led to a 6-fold increase in gap junctional activity compared with that in controls.

In contrast to the abovementioned reports, other studies have suggested that Cx43 may act as an oncogene (12). Ogawa et al investigated the expression of Cx43 in rat hepatocellular carcinoma cells (13) and found that suppression of Cx43 expression in tumor cells reduced the migration and invasion capacity of the cells in vitro and the metastatic ability of the cells in vivo, indicating that Cx43 may have potential as a molecular target for the prevention of cancer metastasis in Cx43-overexpressing tumors. Thus, while Cx43 is often reported to function as a tumor suppressor, differential functions may be observed in the context of different tissue types.

In esophageal cancer, the role of Cx43 has not been sufficiently investigated. Garber et al (7) previously analyzed the expression of Cx43 in neoplastic esophageal epithelial cells in rats. However, the association between Cx43 expression and the clinicopathological characteristics of ESCC has not been previously described. In this study, we aimed to determine the clinicopathological significance of Cx43 expression in ESCC; three main findings were noted: First, Cx43 was expressed at a high frequency in patients with ESCC. Of the 98 ESCC cases, positivity for Cx43 was observed in 62 cases. Second, the survival of patients with high Cx43 expression was significantly poorer compared with that of patients with low Cx43 expression. Third, overexpression of Cx43, as measured by immunohistochemistry, was an independent prognostic indicator in patients with ESCC.

In summary, the prognosis of patients with esophageal cancer remains poor. Therefore, it is crucial to identify prognostic factors for patients with this disease. Several genes have been reported as prognostic factors in patients with esophageal cancer. Our data indicated that Cx43 may be a candidate molecular prognostic marker and molecular target for the development of an effective therapeutic intervention for patients with esophageal cancer.

References